Steve Cohen’s Point72 says it has perfect U.S. compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c
March 21, 2016 8:21 AM EDTCelator Pharmaceuticals (NASDAQ: CPXX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
The following are expected milestones for VYXEOS:
3Q 2016 New Drug Application (NDA) submission1Q 2017 Marketing Authorization Application (MAA) submissionMid-2017 Prescription Drug User Fee Act (PDUFA)... More